FERGUSON, Mark W.J. Appl. No. 10/082,221 March 8, 2004

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-10 (Cancel).

- 11. (New) A method of promoting the healing of a wound or fibrotic disorder with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:
 - i) human IL-10,
- ii) a fragment of human IL-10 that retains the anti-inflammatory healing functionality of human IL-10, and
- iii) a partially modified form of human IL-10, or a fragment thereof, that has at least 60% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10,

sufficient to effect said promotion with reduced scarring.

12. (New) The method according to claim 11, wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

- 13. (New) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.
- 14. (New) The method according to claim 11, wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.
- 15. (New) The method according to claim 11, wherein the agent is administered to a wound site or site of a fibrotic disorder.
- 16. (New) The method according to claim 11, wherein the agent is administered at a concentration of between about $1\mu M$ and about $10\mu M$.
- 17. (New) The method according to claim 16, wherein the agent is administered at a concentration of between about 2.5μM and about 5μM.
- 18. (New) The method according to claim 11 wherein said partially modified form of human IL-10, or fragment thereof, has at least 80% homology with IL-10.

FERGUSON, Mark W.J. A. 1. No. 10/082,221 arch 8, 2004

19. (New) The method according to claim 18 wherein said partially modified form of human IL-10, or fragment thereof, has at least 95% homology with IL-10.